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CASE PRESENTATION
A 62-year-old African-American male with a history of
paraplegia following surgery for removal of a spinal tumor
30 years earlier presented to the Emergency Department
with worsening shortness of breath. He was found to have
congestive heart failure, which responded well to diuresis,
and renal failure with a creatinine concentration of
6.6 mg/dl (583mmol/l). On further questioning, the patient
reported a history of renal dysfunction and hypertension.
The patient had a creatinine concentration of 1.4 mg/dl
(124mmol/l) 10 months before and of 3.0 mg/dl (265mmol/
l) 4 months before. Kidney biopsy had been recom-
mended but was refused by the patient. Past medical
history was significant for a severe decubitus ulcer of the
hip complicated by osteomyelitis and requiring
hospitalization, debridement, and long-term treatment
with antibiotics via an indwelling Hickman catheter,
which was discontinued 1 year before. The patient had
intact bladder function and a history of recurrent cystitis,
but no pyelonephritis. The patient’s only prescription
medication on admission was metoprolol tartrate 75 mg
twice per day. There was no family history of renal disease.
The patient also had a history of significant tobacco use
(1.5 packs per day of cigarettes for 40 years).
Physical examination revealed a well-developed male,
with a blood pressure of 155/75 mmHg, no active
decubitus ulcers, and no evidence of jugular venous
distention. Examination of the lungs revealed diminished
breath sounds at the bases and scattered rhonchi. The
heart was regular in rate and rhythm with no murmurs,
rubs, or gallops. The lower extremities exhibited muscular
atrophy. No lower extremity edema was evident.
Laboratory data were as follows: hematocrit, 34%
(normal range, 42–52%); white blood count, 7.7 109/l
(normal range, 4.0–10.5 109/l); platelet count 418 109/l
(normal range, 150–500 109/l); blood urea nitrogen,
48 mg/dl (17.1 mmol/l) (normal range, 9–20 mg/dl
(3.2–7.1 mmol/l)); 24-h urine protein, 2840 mg; aspartate
aminotransferase, 22 U/l (normal range, 10–40 U/l); alanine
aminotransferase, 14 U/l (normal range, 10–45 U/l); and
serum albumin, 1.7 g/dl (17 g/l) (normal range, 3.5–5.0 g/dl
(35–50 g/l)). Urinalysis revealed 4þ proteinuria and a
bland sediment. Hepatitis C antibody was positive. All
other serologies were negative or normal, including
hepatitis B surface antigen, antinuclear antibody,
antineutrophilic cytoplasmic antibody, and C3 and C4
complement levels.
A chest radiograph showed small bilateral pleural
effusions. An echocardiogram revealed mild left
ventricular hypertrophy but no evidence of infiltrative
disease. A renal sonogram showed normal-sized kidneys,
with a 2.3 cm mass at the lower pole of the left kidney
that was suspicious for malignancy. A renal biopsy was
performed.
RENAL BIOPSY FINDINGS
Light microscopic examination disclosed two cores of renal
cortex containing 31 glomeruli, 10 of which were globally
sclerotic. Glomeruli appeared enlarged and displayed marked
global expansion of the mesangial matrix by amorphous,
eosinophilic, nonargyrophilic material that stained weakly
positive with the periodic acid–Schiff stain and blue-gray
with the trichrome stain (Figure 1a). When stained with
Congo red and viewed under polarized light, apple-green
birefringence diagnostic of amyloidosis was seen (Figure 1b).
The amyloid material also extended segmentally to involve
the glomerular capillary walls. Multiple glomeruli displayed
segmental scars with adhesions to Bowman’s capsule. There
was diffuse, moderate to severe tubular atrophy and
interstitial fibrosis involving approximately 70% of the cortex
sampled and accompanied by moderate chronic interstitial
inflammation. The majority of arterioles and small arteries
were markedly expanded by amorphous, congophilic materi-
al consistent with amyloid (Figure 1c). Larger vessels showed
moderate to severe arteriosclerosis.
Immunofluorescence staining for IgG, IgM, IgA, C3, C1q,
fibrinogen, albumin, and kappa and lambda light chains was
negative in glomeruli. Staining for C3 and IgM was seen in
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arterioles, corresponding to areas of hyalinosis. Immunohis-
tochemical staining for serum amyloid A (SAA) protein, a
marker of secondary/amyloid A (AA) amyloid, was positive
in the distribution of the amyloid deposits (Figure 1d).
Ultrastructural evaluation revealed randomly oriented, non-
branching fibrils within the mesangial matrix and glomerular
basement membrane with a diameter of 12 nm, confirming
the diagnosis of amyloidosis.
PATHOLOGIC DIAGNOSIS
The light and electron microscopic findings, including the
apple-green birefringence when stained with Congo red and
viewed under polarized light and the fibril diameter of 12 nm,
were diagnostic of renal amyloidosis. The negative immuno-
fluorescence staining for kappa and lambda light chains
excluded primary amyloidosis. The positive immunohisto-
chemical staining for SAA in the distribution of the amyloid
deposits confirmed the diagnosis of secondary/AA amylo-
idosis.
DISCUSSION
Amyloidosis is a diverse group of diseases that share in
common the extracellular tissue deposition of randomly
oriented fibrils that measure 8–12 nm in diameter. The
amyloid fibrils are composed of low-molecular-weight
proteins that form b-pleated sheets, best demonstrated by
X-ray crystallography or infrared spectroscopy. The defining
pathologic feature of amyloid deposits is the affinity for
Congo red dye and the property of exhibiting apple-green
birefringence when viewed under polarized light. In all forms
of amyloid, additional components of the deposits include
glycosaminoglycans (i.e. heparan sulfate proteoglycan) and
the amyloid P component.
Amyloidosis is subclassified according to the precursor
protein. In the kidney, the two most common subtypes of
amyloidosis are primary (i.e. light chain) amyloidosis,
in which the amyloid fibrils are composed of immuno-
globulin light chains, and secondary (AA) amyloidosis, in
which the fibrils are derived from SAA, an acute-phase
reactant protein.
Figure 1 | (a) There is global expansion of the mesangial matrix by amorphous, eosinophilic material consistent with amyloid. There is
also mild thickening of some glomerular capillary walls (Hematoxylin and eosin, original magnification 400). (b) The amyloid deposits appear
orangiophilic with the Congo red stain. When viewed under polarized light, apple-green birefringence diagnostic of amyloidosis was seen (not
shown) (original magnification 400). (c) There is marked mural expansion of the walls of arterioles and a small artery by similar-appearing
amorphous material consistent with amyloid. (Hematoxylin and eosin, original magnification 400). (d) Immunohistochemical staining for SAA,
a marker of secondary amyloidosis, is strongly positive in the distribution of the amyloid deposits (original magnification 400).
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Four SAA gene loci have been identified in humans.1 SAA1
and SAA2 products are apolipoproteins synthesized primarily
by the liver and transported in the serum in association with
high-density lipoprotein. SAA3 is a pseudogene, and SAA4
encodes constitutive SAA, which is also synthesized by the
liver. The transcription of the SAA1 and SAA2 genes increases
in response to inflammatory stimuli such as tumor necrosis
factor-a, interleukin 1, and interleukin 6.2 AA is an 8.5 kDa
protein that results from the enzymatic cleavage of the
carboxyl terminus of the 12.5 kDa SAA1 or SAA2 by
macrophages. The two main putative mechanisms thought
to be important in AA amyloidogenesis include increased
synthesis of SAA by hepatocytes in response to acute and
chronic inflammation3 and incomplete proteolysis with
aberrant degradation of SAA to AA protein by macrophages.4
Intrinsic properties of the degradation fragments may also be
important, with smaller fragments preferentially depositing
in glomeruli and larger ones in vessel walls.5
Secondary (AA) amyloidosis occurs in the setting of
chronic immune activation. In the United States and many
developed countries, the most common condition associated
with secondary amyloidosis is rheumatoid arthritis, including
juvenile and adult forms. Other diseases associated with
secondary amyloidosis include ankylosing spondylitis, in-
flammatory bowel disease, psoriasis, Still’s disease, familial
Mediterranean fever, and chronic infections including
tuberculosis, bronchiectasis, chronic osteomyelitis, heroin
abuse with ‘skin popping’,6 and chronic decubitus ulcers. As a
result of improved therapy, the incidence of secondary
amyloidosis has decreased over the past 3 decades and the
demographics have shifted. In the antibiotic era, secondary
amyloidosis is more commonly associated with autoimmune
inflammatory diseases, such as rheumatoid arthritis, and less
commonly associated with chronic infections.7–9
The kidney is the main target of secondary amyloidosis,
with renal involvement noted in 91% of patients in a large
series.7 The first manifestation of secondary amyloidosis
typically is nephrotic-range proteinuria, often associated with
renal insufficiency. Additional symptoms depend on the
organs involved. Outside of the kidney, gastrointestinal
symptoms are most common and include malabsorption,
diarrhea, constipation, and bleeding.7 Unlike the situation in
primary amyloidosis, macroglossia, neuropathy, and con-
gestive heart failure occur infrequently.7,8 Outcomes in
secondary amyloidosis are poor, with a median survival of
24 and 53 months in two series.7,9 Clinical parameters that
adversely influence outcome include cardiac involvement and
the degree of renal insufficiency, hypoalbuminemia, and
proteinuria.7,9–11 In an older series, the most common cause
of death in secondary amyloidosis was uremia, including
complications of dialysis.7 More recently, infection has
emerged as the most common cause of death.9
Treatment of secondary amyloidosis is directed at
controlling the underlying inflammatory process. Examples
include colchicine administration in patients with familial
Mediterranean fever, immunosuppressant therapy (cyclopho-
sphamide, methotrexate, and azathioprine) in patients with
rheumatic diseases, and antibiotics in patients with chronic
infections (such as bronchiectasis, decubitus ulcers, and
chronic osteomyelitis).7 In a recent study of 25 patients with
secondary amyloidosis due to rheumatoid arthritis, ankylos-
ing spondylitis, or psoriatic arthritis, inhibitors of tumor
necrosis factor, including infliximab and etanercept, were
shown to be effective.12 Over a mean follow-up period of 70
weeks, renal function remained stable or improved in 83% of
patients and a 50% decline in proteinuria was achieved in
50% of patients.12 Low-molecular-weight anionic sulfonates
that interfere with the interaction between SAA and heparan
sulfate proteoglycan have been found to be effective in
reducing AA amyloid progression in a murine model,13 and
represent a potential therapeutic strategy for the human
disease.
Renal disease is a frequent complication of spinal cord
injury, accounting for 50% of patient deaths prior to the
availability of hemodialysis and 22% in the post-dialysis
era.14,15 The most common patterns of renal disease seen in
patients with spinal cord injury are chronic pyelonephritis
and secondary amyloidosis.16,14 Secondary amyloidosis has
been found at autopsy in 23–81% of patients with chronic
paraplegia in three series.17,14,16
Secondary amyloidosis typically results from chronic
infection in patients with long-standing spinal cord injury.
Amyloidosis occurs many years after spinal cord injury, with
the most common underlying conditions being chronic
decubitus ulcers, often associated with chronic osteomyelitis,
and chronic pyelonephritis complicating neurogenic blad-
der.14,16–18 A large study found 65 cases of amyloidosis
among 174 autopsies performed on chronic paraplegic
patients dying in the National Spinal Injuries Center in the
United Kingdom.14 In all 65 patients, amyloidosis was
present in the kidney. Among the 65 patients, 60 (92%)
had decubitus ulcers, of which 47 (78%) were associated with
underlying osteomyelitis. Clinical and pathological evidence
of chronic urinary tract infection also was present in all of the
65 patients. In recent years, improved management of
neurogenic bladder and pressure ulcers in spinal cord injury
patients has led to a decrease in the incidences of urinary
tract infections, skin infections, and osteomyelitis. This in
turn has led to a decreased incidence of both chronic
pyelonephritis and secondary amyloidosis.19
The prognosis for secondary amyloidosis in spinal cord
injury patients is somewhat unclear. Efforts should be
directed at prevention of conditions associated with second-
ary amyloidosis. Patients should be carefully screened and
treated for cutaneous ulceration that might lead to decubitus
ulcer formation and for urinary tract infection. With more
severe decubitus ulcers, surgical intervention may be
indicated. When amyloidosis occurs, it is unclear to what
extent antibiotics, chemotherapy, and possibly surgery will
lead to decreased production of fibrils or dissolution of the
existing amyloid deposits. Based upon data collected from
patients with a variety of etiologies of secondary amyloidosis,
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reduction in serum SAA values below a critical level may
lead to regression of amyloid and improved organ function.3
With more advanced disease, renal replacement therapy is
often necessary.
Review of the literature provides little insight into the
prognosis of secondary amyloidosis in patients with spinal
cord injury, in that most of the reported cases come from
older literature and autopsy series. In the few studies that
included living patients, advanced renal failure was present at
the time of diagnosis and did not resolve.14
CLINICAL FOLLOW-UP
Following the renal biopsy, the patient refused further
diagnostic testing, chemotherapy, or hemodialysis. There
was no clinical evidence of rheumatoid arthritis, ankylosing
spondylitis, or inflammatory bowel disease. There was no
history of tuberculosis (and a chest radiograph was
unrevealing). There was no history of drug abuse and no
physical evidence of ‘skin-popping’. The patient’s secondary
amyloidosis was presumed to be related to the previous,
long-standing decubitus ulcer and underlying chronic
osteomyelitis. The patient returned 1 month later with a
potassium of 7.0 mmol/l (normal range, 3.6–5.0 mmol/l) and
a creatinine concentration of 20.6 mg/dl (1821 mmol/l) and
underwent emergent hemodialysis.
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